A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data

SIMPLE SUMMARY: Myelodysplastic syndrome (MDS) is one of the most-common blood cancers in older individuals. Although azacitidine is the most-commonly used treatment for MDS, only 30–40% of patients respond to it, and responses may not be achieved up to six cycles of treatment. Moreover, there are n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharplin, Kirsty, Proudman, William, Chhetri, Rakchha, Tran, Elizabeth Ngoc Hoa, Choong, Jamie, Kutyna, Monika, Selby, Philip, Sapio, Aidan, Friel, Oisin, Khanna, Shreyas, Singhal, Deepak, Damin, Michelle, Ross, David, Yeung, David, Thomas, Daniel, Kok, Chung H., Hiwase, Devendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452100/
https://www.ncbi.nlm.nih.gov/pubmed/37627047
http://dx.doi.org/10.3390/cancers15164019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452100/
https://www.ncbi.nlm.nih.gov/pubmed/37627047
http://dx.doi.org/10.3390/cancers15164019

Ejemplares similares